Objective-Lipid phosphate phosphatase 3 (LPP3), encoded by the PPAP2B gene, is an integral membrane enzyme that dephosphorylates, and thereby terminates, the G-protein-coupled receptor-mediated signaling actions of lysophosphatidic acid (LPA) and sphingosine-1-phosphate. LPP3 is essential for normal vascular development in mice, and a common PPAP2B polymorphism is associated with increased risk of coronary artery disease in humans. Herein, we investigate the function of endothelial LPP3 to understand its role in the development and human disease. Approach and Results-We developed mouse models with selective LPP3 deficiency in endothelial and hematopoietic cells. Tyrosine kinase Tek promoter-mediated inactivation of Ppap2b resulted in embryonic lethality because of vascular defects. LPP3 deficiency in adult mice, achieved using a tamoxifen-inducible Cre transgene under the control of the Tyrosine kinase Tek promoter, enhanced local and systemic inflammatory responses. Endothelial, but not hematopoietic, cell LPP3 deficiency led to significant increases in vascular permeability at baseline and enhanced sensitivity to inflammation-induced vascular leak. Endothelial barrier function was restored by pharmacological or genetic inhibition of either LPA production by the circulating lysophospholipase D autotaxin or of G-protein-coupled receptor-dependent LPA signaling. Conclusions-Our results identify a role for the autotaxin/LPA-signaling nexus as a mediator of endothelial permeability in inflammation and demonstrate that LPP3 limits these effects. These findings have implications for therapeutic targets to maintain vascular barrier function in inflammatory states. (Arterioscler Thromb Vasc Biol. 2014;34:837-845.)
L ipid phosphate phosphatases (LPPs) are integral membrane glycoproteins, originally identified as phosphatidic acid phosphatases, but subsequently shown to dephosphorylate a broader range of lipid substrates, including lysophosphatidic acid (LPA), ceramide-1-phosphate, sphingosine-1-phosphate (S1P), and diacylglycerol pyrophosphate. 1 In mammals, the 3 enzymes, LPP1, LPP2, and LPP3, are encoded by the PPAP2A, PPAP2C, and PPAP2B genes, respectively. 2, 3 LPPs localize to both the plasma membrane and intracellular membrane organelles, with a predicted topology of 6 transmembrane domains and an active site on the extracellular, or luminal surface, of the membrane. Evidence from cultured cells and model organisms identifies an important role for LPPs in dephosphorylating, and thereby inactivating, the G-protein-coupled receptor-mediated extracellular signaling effects of the bioactive lipids LPA and S1P. [4] [5] [6] Although the 3 mammalian LPPs display essentially identical enzymatic activities in vitro and overlapping expression patterns in adult tissues, they are not functionally redundant during the development. Loss of Ppap2c 7 and gene-trap inactivation of Ppap2a 8 in mice does not result in phenotypic alteration, although circulating LPA levels may be lower in the later animals. In contrast, global deletion of Ppap2b in mice results in embryonic lethality, largely because of defects in extraembryonic vascular development. Whether the requirement for LPP3 in vascular development reflects roles for LPA and S1P, or nonenzymatic functions of LPP3 such as regulation of Wnt signaling [9] [10] [11] [12] or integrin interactions, is not presently known.
Recent genetic evidence has focused attention on the possibility that LPP3 may not only be required for vascular development but may also mediate human atherosclerotic disease. Two concurrently published genome-wide association studies identified polymorphisms in the final intron of PPAP2B that associate with increased risk for human coronary artery disease. In a genome-wide association study meta-analysis involving >86 000 individuals, the PPAP2B risk allele independently predicted coronary artery disease (odds ratio, 1.17; P=3.81×10 −19 ) and lacked association with traditional risk factors, such as hypertension, cholesterol, diabetes mellitus, obesity, or smoking. At present, it is not clear whether the risk-associated polymorphism alters LPP3 expression. To provide mechanistic insight into potential roles for LPP3 in the vasculature, we recently reported that targeted deletion of Ppap2b in murine smooth muscle cells enhances vascular inflammation and promotes the development of intimal hyperplasia. In this study, we investigate the consequences of LPP3 deficiency in endothelial and hematopoietic cells. Our findings indicate that LPP3 serves as an intrinsic negative regulator of vascular inflammation through mechanisms that are essential for maintenance of endothelial integrity and protection from inflammation-induced vascular leak. These findings may have broad implications for the development of atherosclerosis and also other disease processes that involved endothelial inflammatory responses.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Tyrosine Kinase Tek-Cre-Mediated Deletion of Ppap2b Results in Embryonic Lethality in Mice
We previously reported that yolk sac vasculature fails to form in mouse embryos lacking LPP3. 13 To explore cellspecific roles for LPP3 during mouse development, we bred Ppap2b fl/fl mice to transgenic mice expressing Cre recombinase under the control of the tyrosine kinase Tek (Tie2) promoter. Heterozygous Tie2-Ppap2b fl/+ mice were viable, fertile, and indistinguishable from their wild-type littermates. Mating of male Tie2-Ppap2b fl/+ with female Ppap2b fl/+ mice on either a mixed B6/129 or pure background failed to generate any Tie2-Ppap2b Δ animals postnatally, suggesting that the absence of LPP3 expression in a combination of endothelial and hematopoietic cells results in embryonic lethality. Analysis at E9.5 and E10.5 revealed a normal Mendelian distribution of genotypes, but no viable Tie2-Ppap2b Δ embryos were identified after E12.5. Tie2-Ppap2b Δ embryos share many features observed in embryos globally lacking Ppap2b expression, such as a delay in the development compared with littermates, vascular defects represented by pale yolk sacs with accumulation of erythrocytes, and signs of hemorrhage in the embryo proper. Defective chorio-allantoic fusion was observed in some embryos. In an embryo pair matched to 22 pairs of somites (Figure 1 ), the Tie2-Ppap2b Δ embryo displayed hemorrhage in the tail region, smaller common atrial chamber, an abnormal aortic sac, collapsed outflow tract lumen, an abnormal swelling of the third branchial arch artery, open atrioventricular canal, and irregular intersomitic vasculature. Many of these characteristics are consistent with loss of hemodynamics and vascular permeability. These vascular abnormalities, along with the lack of survival at birth in Tie2-Ppap2 Δ mice, are consistent with previous observations that in E10.5 chimeric embryos formed by injection of Ppap2b −/− embryonic stem cells into Rosa26 blastocysts, wild-type endothelial cells predominately formed umbilical cord vessels without significant contribution from Ppap2b −/− cells. 14 Together, these observations indicate that endothelial LPP3 is essential for normal vascular development.
Inducible Inactivation of Ppap2b in Adult Mice
To generate a Ppap2b null allele in vascular endothelium of adult animals, Ppap2b fl/fl mice were crossed with transgenic mice expressing a recombinant estrogen receptor-Cre fusion protein under the control of the Tie2 promoter (ERT2-Cre) to generate ERT2-Ppap2b ∆ mice. The activity of the promoter was regulated by administering the estrogen antagonist tamoxifen. Tamoxifentreated Ppap2b fl/fl and ERT2-Ppap2b ∆ mice were compared experimentally. Absence of LPP3 expression in ERT2-Ppap2b ∆ mice was confirmed by immunostaining of endothelial cells in newly formed vessels in Matrigel implants supplemented with basic fibroblast growth factor ( Figure 2A ). Neovascularization was quantified with fluorescein isothiocyanate-dextran administered intravenously. Vessel formation in the Matrigel plugs was scored by size (small [<10 μm], medium [10-20 μm], and large [>20 μm]; Figure 2B and 2C). In comparison with vessels that formed in Matrigel implanted in Ppap2b fl/fl mice, those in the ERT2-Ppap2b ∆ mice were smaller and fewer vessels formed in the center of the plugs (P<0.001; Figure 2C ), which is in keeping with previous reports that antibodies to LPP3-inhibited capillary morphogenesis in vitro. 15 Ppap2b mRNA levels were ≈2-fold lower in lungs of ERT2-Ppap2b ∆ mice ( Figure 3A) . No difference was observed in Ppap2a or Ppap2c mRNA levels, encoding LPP1 or LPP2, respectively. Immunoblot analysis of lung tissue indicated that LPP3 levels were reduced in ERT2-Ppap2b ∆ lungs ( Figure 3B ), as was lipid phosphatase activity measured in LPP3 immunoprecipitates ( Figure 3C ). Immunohistochemical analysis of lung tissue indicated that LPP3 was not present in endothelial cells ( Figure 3D ). The remaining LPP3 expression and activity in lungs of ERT2-Ppap2b ∆ mice are likely from epithelial, alveolar, or other cells. No difference was observed in complete blood counts of the Ppap2b fl/fl and ERT2-Ppap2b ∆ mice (Table) . Likewise, heart rates were similar in Ppap2b fl/fl (645±45 bpm; n=16) and ERT2-Ppap2b ∆ mice (630±60 bpm; n=16). Interestingly, systolic blood pressure was significantly lower in ERT2-Ppap2b ∆ mice (92±8 mm Hg; n=16) compared with Ppap2b fl/fl mice (100±7 mm Hg; n=16; P<0.001).
Enhanced Inflammatory Responses in Mice Lacking LPP3 in Hematopoietic and Endothelial Cells
Because the Tie2 promoter is also active in some hematopoietic cells, we investigated leukocyte LPP3 expression in the ERT2-Ppap2b ∆ mice. We previously reported that neutrophils isolated from peripheral blood robustly express LPP3. 16 At 4 hours after administration of thioglycolate intraperitoneally, significantly more leukocytes infiltrated the peritoneum of ERT2-Ppap2b ∆ mice ( Figure 4A ); these infiltrating cells lacked LPP3 ( Figure 4B ). To determine whether the ERT2-Ppap2b ∆ mice display enhanced inflammatory responses to other challenges, endotoxin (lipopolysaccharide [LPS]; 2 mg/kg IP) was administered to the animals. As expected, LPS exposure elevated plasma inflammatory cytokines above vehicle treatment ( Figure 4C and 4D). In ERT2-Ppap2b ∆ mice, LPS-induced expression of interleukin-6 ( Figure 4C ) and KC ( Figure 4D ) was 3.3±0.5-fold and 1.9±0.6-fold higher, respectively, than in LPS-treated Ppap2b fl/fl mice. Analysis of plasma by cytokine antibody array confirmed the elevation in interleukin-6 and KC ( Figure 4E ) and indicated that macrophage inflammatory protein 2 and regulated on activation, normal T cell expressed and secreted were also higher in ERT2-Ppap2b ∆ plasma 4 hours after LPS administration, whereas granulocyte colony stimulating factor, soluble intracellular adhesion molecule 1, macrophage colony stimulating factor, and chemokine ligand 9 seemed lower than in Ppap2b fl/fl mice. We investigate the role of monocytes in the LPS response by pretreating animals with liposomal-clondronate to deplete >90% of circulating monocytes. Plasma interleukin-6 levels in ERT2-Ppap2b ∆ mice were not affected by monocyte deletion before LPS administration (8730±1481 versus 8840±433 in the absence or presence of clondronate).
Disruption in Barrier Function in Mice Lacking Endothelial LPP3 Is Autotaxin and LPA Dependent
Inflammation is characteristically accompanied by an increase in vascular endothelial permeability. We therefore investigated extravasation of Evans blue dye (EBD) into lung as a measure of the integrity of the endothelial barrier. The absence of LPP3 in ERT2-Ppap2b ∆ mice resulted in a 2.2±0.5-fold increase in basal vascular permeability, as measured by EBD accumulation in the lungs ( Figure 5A ). LPS increased vascular permeability in both Ppap2b fl/fl and ERT2-Ppap2b ∆ mice, the latter experiencing significantly more vessel leak ( Figure 5A ). To confirm that endothelial (but not bone marrow) cell-derived LPP3 was required for maintenance of the endothelial barrier, chimeric mice were created by bone marrow transplantation and then treated with tamoxifen. The vascular barrier defect followed the genotype of the recipient mice (lacking LPP3 in vessels) and not the genotype of the transplanted marrow ( Figure 5B ). These survival doses of LPS did not elicit significant inflammatory cell infiltration in lungs of either Ppap2b fl/fl or ERT2-Ppap2b ∆ mice, and no differences in macrophage accumulation in lung was observed between the 2 genotypes ( Figure 5C ).
Because LPP3 may terminate vascular endothelial cell signaling responses to the bioactive lipids S1P and LPA, a lack of LPP3 could result in enhanced signaling actions of either bioactive mediator. S1P is known to maintain endothelial barrier function, so we hypothesized that lower endothelial LPP3 expression might increase S1P signaling, which, in turn, could downregulate S1P receptors, resulting in an increase in endothelial permeability, as has been reported with long-term administration of S1P agonists. 17 To determine whether ERT2-Ppap2b ∆ mice demonstrated impairments in the response to S1P, the ability of S1P to promote endothelial barrier function was examined. In both Ppap2b fl/fl and ERT2-Ppap2b ∆ mice, S1P enhanced barrier function after LPS administration, suggesting that the defect in the ERT2-Ppap2b ∆ mice was not because of downregulation of S1P receptor signaling ( Figure I in the online-only Data Supplement). In keeping with these observations, no difference in lymphocyte expression of S1PR1 between Ppap2b fl/fl and ERT2-Ppap2b ∆ mice was observed by flow cytometry.
We next examined whether increases in LPA signaling could account for vascular leak in the ERT2-Ppap2b ∆ mice, as LPA has been reported to promote endothelial permeability in culture models. 18, 19 Two strategies were used to target LPA signaling. First, the potent autotaxin inhibitor PF8380 20 was administered to mice to reduce the generation of extracellular, bioactive LPA by autotaxin, which is a secreted lysophospholipase D responsible for production of bioactive LPA. In keeping with the ability to inhibit autotaxin, PF8380 decreased plasma LPA levels (control, 248±29; PF8380, 173±55 nmol/L; P=0.0154 paired t test). PF8380 also reduced vascular permeability in both Ppap2b fl/fl and ERT2-Ppap2b ∆ in response to LPS ( Figure 6A) . Similarly, administration of the pan-LPA receptor antagonist, Values are mean±SD. Hb indicates hemoglobin (mg/dL); HCT, hematocrit (%); LY, lymphocyte (10 3 /μL); MO, monocyte (10 3 /μL); MPV, mean platelet volume (nL); NE, neutrophil (10 3 /μL); Plt, platelet count (10 6 /μL); and WBC, white blood cell count (×10 3 /μL). α-bromomethylene phosphonate, BrP-LPA, resulted in a 2-fold reduction in LPS-promoted permeability in ERT2-Ppap2b ∆ mice at baseline and in response to LPS ( Figure 6B ). To complement these pharmacological studies of the role of LPA in regulation of endothelial permeability, we used mice with genetic inactivation of the LPA-generating enzyme autotaxin or G-protein-coupled LPA receptors. Global deficiency of autotaxin (encoded by the Enpp2 gene) is embryonically lethal in mice. We established Enpp2 fl/fl mice harboring the Cre recombinase under the control of the interferon-inducible Mx-1 promoter and stimulated expression of the Cre transgene with pI-pC ( Figure 6C ). The Mx1-Enpp2 ∆ mice displayed reduced plasma levels of autotaxin and were protected from endothelial permeability after LPS challenge ( Figure 6C ). Consistent with a role for autotaxin-generated LPA in LPS-induced vascular permeability, mice lacking LPA receptors 1 and 2 (LPA1 and LPA2) or LPA receptor 4 (LPA4) demonstrated less EBD accumulation in lungs after LPS than did wild-type controls ( Figure II in the online-only Data Supplement). Finally, we directly tested the ability of LPA to stimulate vascular permeability using the Miles assay. Intradermal administration of LPA dose-dependently increased EBD accumulation in the skin of wild-type mice but not of LPA1 −/− , LPA2 −/− , or LPA4 −/− mice, indicating that these receptors mediate LPA-induced vascular leak ( Figure II in the online-only Data Supplement).
The observation that the barrier defect tracked with the absence of LPP3 in vascular (but not marrow) cells in chimeric mice suggested a critical role for endothelial LPP3. We used ventilated/perfused lungs to probe the role of endothelial LPP3 in inflammation-induced vascular permeability. In buffer-perfused lungs, LPS administered via the pulmonary artery increased EBD accumulation in the lungs of Ppap2b fl/fl mice and, to a greater extent, ERT2-Ppap2b ∆ mice ( Figure 6D) . The pan-LPA receptor antagonist BrP-LPA attenuated endothelial permeability in both Ppap2b fl/fl and ERT2-Ppap2b ∆ mice ( Figure 6B) .
The results described above establish a role for LPP3 in maintaining the integrity of the endothelial barrier that we hypothesize is because of the enzyme's ability to terminate the barrier-enhancing actions of autotaxin-derived LPA that are mediated by G-protein-coupled LPA receptors. Therefore, we investigated whether plasma LPA levels were altered in the absence of LPP3 and observed no difference in circulating LPA levels in Ppap2b fl/fl and ERT2-Ppap2b∆ mice. We also measured the rate of elimination of exogenously administered LPA and S1P. The lack of endothelial LPP3 in adult mice did not alter the rapid rate of elimination of single-bolus doses of either C17-LPA or C17-S1P from blood ( Figure III in the online-only Data Supplement). Taken together, our findings suggest that endothelial LPP3 does not play a role in determining plasma LPA levels or in the rapid elimination of LPA and S1P from plasma but may function as a localized regulator of signaling through the autotaxin-LPA nexus.
Discussion
The endothelium forms a highly selective barrier between blood and tissue that is characteristically compromised during inflammation. We report that Tie2 promoter-driven deficiency of LPP3 impairs embryonic vascular development, resulting in embryonic lethality, and disrupts normal endothelial barrier function postnatally. Although the Tie2 promoter strategy used will result in deficiency of LPP3 in endothelial and some hematopoietic cells, the onset of the embryonic phenotype suggests a fundamental role for the enzyme in endothelial cells during early development. Endothelial and hematopoietic LPP3 deficiency also heightens inflammatory responses in adult animals. These findings imply that LPP3 expression is essential for normal prenatal vascular development and, in adult mice, LPP3 normally functions to maintain vascular integrity and to attenuate inflammation.
Although the mechanistic basis of the requirement for LPP3 during vascular development remains to be established, our results suggest that in adult mice a major function of LPP3 is to attenuate LPA-mediated increases in permeability of the vascular endothelium. In support of this theory, we found that genetic and pharmacological approaches to attenuate LPA signaling or reduce LPA production by autotaxin preserved endothelial barrier function in the setting of an inflammatory challenge. Moreover, LPA itself promoted protein extravasation from the vasculature in an LPA receptor-dependent manner. These observations are in keeping with reports in cell culture systems in which LPA was found to increase endothelial permeability by stimulating Rho-mediated actomyosin contractility. [21] [22] [23] After bleomycin-induced lung injury, mice lacking LPA1 display reduced pulmonary fibrosis and less vascular leak, 24 which is in agreement with our finding of a role for LPA1 and LPA4 receptors in mediating protein extravasation in lung after LPS challenge. Because genetic deficiency of LPP3 in adult mice was not associated with decreases in either circulating LPA levels or the rate of elimination of exogenously supplied LPA from the circulation, we consider it likely that LPP3 functions primarily to regulate vascular endothelial celllocalized LPA production and signaling pathways, leading to changes in vascular permeability. Taken together, these findings suggest that autotaxin-LPA signaling may elicit a loss of vascular integrity by preventing tight-junction formation, and that either autotaxin inhibitors or LPA receptor antagonists might be useful in the treatment of endothelial dysfunction and tissue injury in inflammation.
Although we did not establish the molecular mechanism underlying embryonic lethality in Tie2-Ppap2b ∆ mice, emerging evidence supports a role for LPA in directing vascular development. Global deletion of autotaxin results in early embryonic lethality in mice, and knockdown of zebrafish autotaxin causes aberrant connections to form between segmental arteries that sprout from the dorsal aorta. 25 These findings indicate that tight, spatially restricted regulation of LPA metabolism and signaling is important for proper cell migration during embryonic development. Indeed, we recently reported that autotaxin localizes to the leading edge of migrating cells through integrin-mediated recruitment and directs the path of migration. 26 Based on these observations, we hypothesize that it may be possible that at least part of the role of LPP3 is to regulate localized LPA levels during the development. In support, mammalian LPP3 can complement mutations in Drosophila LPPs encoded by the Wun and Wun2 genes, which guide migrating germ cells in the developing embryo through mechanisms that seem to involve localized inactivation of an attractive lipid signal. Experiments with ectopic expression of Wunens indicate that they regulate a diffusible lipid signal in a cell contact-independent manner, with an effective range of ≈33 μm. 27 These observations are all consistent with ours and support the contention that LPA or another diffusible lipid signal could account for the requirement for endothelial LPP3 during development. In addition to LPA, S1P is a possible candidate mediator. S1P signaling through S1PR1 is also essential for blood vessel formation, 28 although the requirements for S1P and S1PR1 seem to be fundamentally distinct from those of LPP3. In addition, LPP3 also has nonenzymatic functions that may be mediated by integrin binding or β-catenin signaling, 12, 29, 30 which could be required during development.
In addition to the endothelial defects in ERT2-Ppap2b ∆ mice, we observed heightened inflammatory responses in leukocyte accumulation in peritonitis and in cytokine responses to endotoxin, indicating that endothelial and hematopoietic LPP3 function to limit systemic inflammation. These findings are similar to our observations that LPP3 attenuates inflammation after vascular injury on vascular smooth muscle cells. LPA regulates inflammation by stimulating the release of cytokines [31] [32] [33] [34] and inflammatory mediators that modulate movement of inflammatory cells. Thus, as with its role in regulation of endothelial permeability, the anti-inflammatory effects of LPP3 may stem from its ability to limit localized LPA signaling. Interestingly, although vascular permeability changes were observed with endotoxin, heightened leukocyte accumulation in lung was not demonstrated in ERT2-Ppap2b ∆ mice. We do not have an explanation for why peritoneal but not pulmonary white cell accumulation was affected by LPP3, although the differences could be because of the nature of the inflammatory challenge or vascular bed-specific mechanisms or both. The ability of LPP3 to modulate vascular inflammatory responses may provide a mechanistic link between the risk of coronary artery disease associated with a polymorphism in PPAP2B. Our observations indicate that genetic or environmental factors that downregulate LPP3 levels would predispose individuals to heightened vascular inflammation and permeability and thereby might exacerbate atherosclerosis.
Research from our group and others indicates that circulating LPA levels are dynamically regulated with steady-state levels maintained by a balance between autotaxin-mediated LPA generation and less well-defined mechanisms, which result in rapid elimination of circulating LPA. 35, 36 Elimination of intravenously supplied LPA and S1P was unaffected in the ERT2-Ppap2b∆ mice, suggesting that either endothelial LPP3 is not responsible for the bulk of their clearance from plasma or that different cells are involved. These observations are in keeping with our recent findings of elimination of LPA. 37 At the present time the mechanism(s) responsible for rapid removal of LPA and S1P from circulation is not known, although clearance by the liver is involved. 37 In summary, our work substantiates and extends observations that the bioactive lipid LPA is an important regulator of systemic inflammation and vascular permeability and defines a previously unappreciated role for LPP3 as a negative regulator of these processes. Our observations have broad relevance for understanding the link between a common heritable genetic variant of the PPAP2B gene that encodes LPP3 and human cardiovascular disease risk and suggest that pharmacological approaches to limit LPA production and signaling would be of benefit for cardiovascular disease prophylaxis and also, perhaps, for the acute treatment of systemic inflammation and vascular permeability associated with sepsis.
